November 05, 2025

Get In Touch

Monitoring Epstein-Barr Viral Load After Liver Transplant May Reduce Risk For Rare Posttransplant Complication

A study of adult recipients of liver transplants has found that monitoring transplant recipients for Epstein-Barr virus viral load (EBV VL) helped to reduce risk for posttransplant lymphoproliferative disease (PTLD), a rare but serious potential complication of transplantation.
The findings are published in Annals of Internal Medicine.
Primary infection with or reactivation of EBV can occur after liver transplant and can lead to PTLD. An EBV VL monitoring strategy, including the reduction of immunosuppression is hypothesized to reduce incidence of PTLD in adult transplant recipients -almost all IgG anti-EBV positive).
Researchers from the Transplantation Centers of Leiden University Medical Center and Erasmus Medical Center, The Netherlands studied health records for adult recipients of first liver transplant at these two university medical centers in Leiden and Rotterdam to examine the effect of an EBV VL monitoring strategy on the incidence of PTLD during long-term follow-up after liver transplant in adults. The researchers conducted a difference-in-difference analysis among 4 groups. Adult recipients of first liver transplant in Leiden between September 2003 and January 2017 with an EBV VL monitoring strategy formed the monitoring group; recipients of first liver transplant in Rotterdam between January 2003 and January 2017 without such a strategy formed the contemporary control group; and those who had transplants in Leiden between September 1992 and September 2003 or Rotterdam between 1986 and January 2003 formed the historical control groups.
The analysis showed a numerically larger within-hospital decrease in PTLD in Leiden-with EBV VL monitoring strategy in the contemporary cohort-over time than in Rotterdam-without EBV VL monitoring strategy. According to the authors, these findings suggest that an EBV VL monitoring policy -with reduction of immunosuppression in case of EBV VL detection- should be considered in transplant programs to avoid over-immunosuppression and thereby reduce the incidence of PTLD.
Reference:
Bastian N. Ruijter, Ron Wolterbeek, Mitchell Hew, Marjolein van Reeven, Danny van der Helm, Jeroen Dubbeld, Maarten E. Tushuizen, Herold Metselaar, Ann C.T.M. Vossen, and Bart van Hoek, https://doi.org/10.7326/M22-0364

Disclaimer: This website is designed for healthcare professionals and serves solely for informational purposes.
The content provided should not be interpreted as medical advice, diagnosis, treatment recommendations, prescriptions, or endorsements of specific medical practices. It is not a replacement for professional medical consultation or the expertise of a licensed healthcare provider.
Given the ever-evolving nature of medical science, we strive to keep our information accurate and up to date. However, we do not guarantee the completeness or accuracy of the content.
If you come across any inconsistencies, please reach out to us at admin@doctornewsdaily.com.
We do not support or endorse medical opinions, treatments, or recommendations that contradict the advice of qualified healthcare professionals.
By using this website, you agree to our Terms of Use, Privacy Policy, and Advertisement Policy.
For further details, please review our Full Disclaimer.

0 Comments

Post a comment

Please login to post a comment.

No comments yet. Be the first to comment!